Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Investors soured on the sector when Elevance, an insurer, handed in disappointing results and shared a downbeat outlook.

Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Over the last 7 days, the United States market has remained flat, yet it has experienced a notable 12% rise over the past year with earnings forecasted to grow by 15% annually. In such an environment, ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

Stocks rose Thursday as investors responded to a flurry of quarterly earnings reports from major companies and better-than-expected retail sales data.

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...